CEO message

In recent years, the reasons for failure of drug development programs have been the subject of much discussion.  Although adverse effects, toxicity, or pharmacokinetic features are often cited as reasons for arrested drug development, a review of the portfolio performance of AstraZeneca (Cook D, et al.. Nat Rev Drug Discov. 2014; 13:419–431) suggests failures in Phase II studies are caused by a lack of efficacy. This probably results from differences in behavior of the drug target in the assay systems compared with the target behavior in patients. Most of the time, the pre-clinical pharmacology for many of these agents is established in cell culture, an oversimplified physiological microenvironment.

At Humana Biosciences we believe that drug screening can be improved with the use of human cells ideally derived from patients and then cultured in the most physiologically relevant conditions.

That is why our mission is to develop and commercialize in vitro experimental models based on the use of human cells and tissues coming from patients having the pathology of interest.

Moreover, in our laboratories, we are constantly working to set up the most relevant models of experimental pathologies to be used for in vivo proof of concept, based on the best predictive animal species and phenotypes, including transgenic animals.